Sezer Atakan, Celik Mehmet, Yilmaz Bulbul Buket, Can Nuray, Tastekin Ebru, Ayturk Semra, Ustun Funda, Guldiken Sibel, Sut Necdet
Department of Surgery, Faculty of Medicine, Trakya University, Edirne, Turkey.
Bosn J Basic Med Sci. 2017 May 20;17(2):144-151. doi: 10.17305/bjbms.2017.1924.
Lymphovascular invasion (LVI) is an important prognostic factor in various solid tumors, however, data on the association between LVI and thyroid carcinomas are limited. In this study, we evaluated the relationship between LVI and clinicopathological features of papillary thyroid carcinoma (PTC). Six hundred seventy-eight patients diagnosed with PTC between 2012 and 2015 were included into the study. Patients were classified based on the presence or absence of LVI. Gender, age, ultrasonography (US), tumor size and multifocality, BRAFV600E mutation, perineural and capsular invasion, extrathyroid extension (ETE), nodal metastasis, and recurrences were evaluated, and risk analysis was performed for each parameter. The number of patients with LVI [LVI (+)] was 63, while the number of patients without LVI [LVI (-)] was 615. The female/male ratio was 564/114. LVI was present in 18.4% of male patients and in 7.4 % of female patients. In the age group between 17-25 years LVI was detected in 6/13 patients, and this result was statistically significant compared to other age groups (p = 0.004). Suspicious lymph nodes upon US, perineural or capsular invasion, ETE, tumor size, and nodal metastasis were significantly more frequent in LVI (+) group (p < 0.001). The frequency of BRAFV600E mutation was also significantly higher in LVI (+) group (p < 0.001). Overall, the presence of LVI was associated with gender, tumor size, age, lymph node metastasis, pathological lymph nodes, perineural and capsular invasion, ETE, and BRAFV600E mutation. These results suggest that in PTC patients undergoing thyroidectomy, the presence of LVI should be considered as an indicator of aggressive clinicopathological features and those patients should be followed up carefully for recurrences and metastasis.
淋巴管侵犯(LVI)是多种实体瘤的重要预后因素,然而,关于LVI与甲状腺癌之间关联的数据有限。在本研究中,我们评估了LVI与甲状腺乳头状癌(PTC)临床病理特征之间的关系。纳入了2012年至2015年间诊断为PTC的678例患者。根据是否存在LVI对患者进行分类。评估了性别、年龄、超声检查(US)、肿瘤大小和多灶性、BRAFV600E突变、神经周围和包膜侵犯、甲状腺外扩展(ETE)、淋巴结转移和复发情况,并对每个参数进行了风险分析。有LVI [LVI(+)]的患者有63例,而无LVI [LVI(-)]的患者有615例。男女比例为564/114。18.4%的男性患者和7.4%的女性患者存在LVI。在17 - 25岁年龄组中,13例患者中有6例检测到LVI,与其他年龄组相比,该结果具有统计学意义(p = 0.004)。LVI(+)组中超声检查可疑淋巴结、神经周围或包膜侵犯、ETE、肿瘤大小和淋巴结转移明显更常见(p < 0.001)。LVI(+)组中BRAFV600E突变的频率也明显更高(p < 0.001)。总体而言,LVI的存在与性别、肿瘤大小、年龄、淋巴结转移、病理性淋巴结、神经周围和包膜侵犯、ETE以及BRAFV600E突变有关。这些结果表明,在接受甲状腺切除术的PTC患者中,LVI的存在应被视为侵袭性临床病理特征的指标,应对这些患者进行仔细的复发和转移随访。